RGX-314 在脉络膜上腔对糖尿病视网膜病变参与者的长期随访研究
一项长期随访研究,以评估脉络膜上腔给药 RGX-314 治疗无中心受累的糖尿病性视网膜病变-糖尿病性黄斑水肿的安全性和有效性
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85014
- Retinal Research Institute, LLC
-
-
California
-
Bakersfield、California、美国、93309
- California Retina Consultants
-
Beverly Hills、California、美国、90211
- Retina-Vitreous Associates Medical Group
-
Los Angeles、California、美国、90017
- Retinal Diagnostic Center
-
Mountain View、California、美国、94040
- Northern California Retina Vitreous Associates Medical Group Inc
-
Pasadena、California、美国、91107
- California Eye Specialists Medical Group, Inc
-
Poway、California、美国、92064
- Retina Consultants San Diego
-
Santa Barbara、California、美国、93103
- California Retina Consultants CRC
-
-
Georgia
-
Augusta、Georgia、美国、30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Forest、Illinois、美国、60452
- University Retina and Macula Associates, PC
-
-
Maryland
-
Hagerstown、Maryland、美国、21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Ophthalmic Consultants of Boston
-
-
Nevada
-
Reno、Nevada、美国、89502
- Sierra eye Associates
-
-
New Jersey
-
Teaneck、New Jersey、美国、07666
- New Jersey Retina
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87109
- Vision Research Center Eye Associates of New Mexico
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- Duke University
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107
- Mid Atlantic Retina
-
-
Tennessee
-
Germantown、Tennessee、美国、38138
- Charles Retina Institute, P.C
-
-
Texas
-
Austin、Texas、美国、78750
- Austin Clinical Research
-
The Woodlands、Texas、美国、77384
- Retina Consultants of Texas
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Must provide written, signed informed consent for this study
- Must have been enrolled in a previous clinical study of ABBV-RGX-314 for the treatment of DR with or without CI-DME and must have received an SCS injection of ABBV-RGX-314 in that study
- Must be willing and able to comply with all study procedures
Exclusion Criteria:
- None
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Standard of Care
Dose Level (DL) 1-3 participants who received ABBV-RGX-314 in a parent study will continue to receive standard of care for the study duration. |
Standard of Care |
|
其他:Supplemental Treatment
DL4 participants from parent study will be eligible to receive supplement aflibercept through a prespecified timepoint based on protocol-specified criteria if they develop worsening CI-DME or high-risk proliferative diabetic retinopathy (PDR) in the study eye. |
Standard of Care Injection
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)
大体时间:5 years inclusive of the parent study
|
To evaluate the long-term safety of ABBV-RGX-314 |
5 years inclusive of the parent study
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
需要对眼部糖尿病并发症进行任何额外干预的参与者比例(例如,抗 VEGF 玻璃体内注射或 PRP)
大体时间:5 年,包括家长学习
|
5 年,包括家长学习
|
|
患有任何威胁视力的眼部糖尿病并发症的参与者比例
大体时间:5 年,包括家长学习
|
5 年,包括家长学习
|
|
Incidences of non-ocular AEs and any Adverse Events of Special Interest
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in DR by ETDRS-DRSS on digital stereoscopic fundus photography
大体时间:5 years, inclusive of the parent study
|
5 years, inclusive of the parent study
|
|
Proportion of participants achieving 0-step (no change), a ≥1-step, a ≥2-step, or a ≥3-step or greater change in DR per ETDRS-DRSS on digital stereoscopic fundus photography from baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Proportion of participants gaining or losing ≥ 5, 10, and 15 letters in BCVA compared with baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CST as measured by SD-OCT
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in the area of retinal nonperfusion on ultra-widefield Optos FA
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of anti-VEGF injections through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of anti-VEGF injections in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean anti-VEGF injection annualized rate through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean anti-VEGF injection annualized rate in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of retina specialist visits attended for complications of DR based on chart review
大体时间:5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
合作者和调查者
赞助
合作者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- RGX-314-5201 (M23-420)
- M23-420 (其他标识符:AbbVie Inc)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 共享时间框架
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 共享访问标准
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.